TWST NASDAQ
Credit Risk of going bust: lower than 76% of companies Debt: 1.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.04 (down more than 99.9%), Twist Bioscience Corporation would be worth roughly what it owes.
Total debt $93.6M against a stock market value of $9.56B.
Distance to default 8.74 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $8.6M (short-term plus half of long-term), stock volatility 77.3%; Altman Z'' -4.23. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
South San Francisco, CA 94080
US
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Laponis Adam | S-Sale | 2,462 | $156.30 | 2026-10-09 |
| Leproust Emily M. | S-Sale | 1,840 | $200.44 | 2026-10-05 |
| Leproust Emily M. | S-Sale | 481 | $201.26 | 2026-10-05 |
| Leproust Emily M. | S-Sale | 1,017 | $202.32 | 2026-10-05 |
| Leproust Emily M. | S-Sale | 432 | $203.61 | 2026-10-05 |